CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma
PDF | HTML | How to cite
Metrics: PDF 1812 views | HTML 1801 views | ?
Jing Wei1, Guanzhen Yu2, Genbao Shao1, Aiqin Sun1, Miao Chen1,3, Wannian Yang1, Qiong Lin1
1School of Medicine, Jiangsu University, Zhenjiang, Jiangsu, China
2Changzheng Hospital, Shanghai, China
3The Affiliated Hospital, Jiangsu University, Zhenjiang, Jiangsu, China
Qiong Lin, e-mail: [email protected]
Wannian Yang, e-mail: [email protected]
Keywords: gastric cardia adenocarcinoma, CYR61, prognostic biomarker, metastasis, cell migration
Received: January 04, 2016 Accepted: March 31, 2016 Published: April 20, 2016
Gastric cardia adenocarcinoma (GCA) is the most aggressive subtype of gastric cancer with a high metastatic rate. In this report, we collected tumor tissue samples from 214 GCA cases and examined expression of CYR61, a target gene product of the Hippo-YAP/TAZ pathway, in the GCA tumors by immunohistochemical (IHC) staining using the tissue microarray assay (TMA). The results have shown that CYR61 is overexpressed in 44% of the GCA tumor samples. Expression of CYR61 is inversely correlated with cumulative survival of GCA patients (p<0.001) and significantly associated only with metastatic pathological categories (with N category, p=0.052; with TNM stage, p=0.001). Furthermore, knockdown of CYR61 in gastric cancer AGS cells impairs the cancer cell migration and invasion, suggesting a driver role of CYR61 in metastasis. Thus, our studies have established CYR61 as a metastatic biomarker for prediction of poor prognosis of GCA and provided a potential molecular target for anti-metastatic therapy of GCA.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.